Indietro

Selezionare la regione

Azienda

Richiedi un consulto sulle cellule staminali

Per saperne di più

I nostri
trapianti

Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:

Immagine
Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:
Nr. Fonte Tipo di fonte Diagnosi Settore medico Anno di applicazione Terapia Paese Età del destinatario
301 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 33
302 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Switzerland 69
303 Apheresis Allogeneic CML Blast Crisis Hematology 2026 Standard Therapy Poland 38
304 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy India 34
305 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Bulgaria 49
306 Apheresis Allogeneic Hodgkin lymphoma Hematology 2026 Standard Therapy Russian Federation 37
307 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 65
308 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 24
309 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 58
310 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 69
311 Apheresis Allogeneic Chronic Lymphocytic Leukemia Hematology 2026 Standard Therapy Poland 63
312 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Belgium 64
313 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Argentine 52
314 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 71
315 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 55
316 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 75
317 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 69
318 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Poland 12
319 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 71
320 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Switzerland 66
321 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 63
322 Apheresis Allogeneic T -Cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 45
323 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Croatia 57
324 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 40
325 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Kazachstan 8
326 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 65
327 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 66
328 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 68
329 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 65
330 Apheresis Allogeneic Diffuse Large B-Cell Lymphoma Hematology 2026 Standard Therapy Germany 63
331 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 66
332 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 44
333 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 57
334 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy UK 62
335 Apheresis Allogeneic Aplastic Anemia Hematology 2026 Standard Therapy Poland 22
336 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 72
337 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 68
338 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Belgium 63
339 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 47
340 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Poland 51
341 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 70
342 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Bulgaria 28
343 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
344 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 73
345 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 69
346 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 10
347 Apheresis Allogeneic T-cell non-Hodgkin lymphoma / NK Hematology 2026 Standard Therapy Poland 19
348 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Belgium 48
349 Apheresis Allogeneic Essential Thrombocythemia Hematology 2026 Standard Therapy USA 59
350 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Ukraine 58
351 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 72
352 Apheresis Allogeneic B-ALL B-cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Netherlands 71
353 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Poland 59
354 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 67
355 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 67
356 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 37
357 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 66
358 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 48
359 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 15
360 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2026 Standard Therapy USA 45
361 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 61
362 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 43
363 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 64
364 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 29
365 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Switzerland 69
366 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 61
367 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 67
368 Apheresis Allogeneic Orofacial Myofunctional Disorders (OMDS); Primary Myelofibrosis (PMF) to secondary Acute Myeloid Leukemia (AML) Hematology 2026 Standard Therapy Germany 36
369 Apheresis Allogeneic Chronic Myeloid Leukemia Hematology 2026 Standard Therapy USA 66
370 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 66
371 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 57
372 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy India 51
373 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 25
374 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 35
375 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Finland 40
376 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 49
377 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 66
378 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 67
379 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 50
380 Apheresis Allogeneic T Lymphblastic Leukemia/Lymphoma Hematology 2026 Standard Therapy Canada 43
381 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy France 74
382 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 67
383 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 59
384 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 44
385 Apheresis Allogeneic Multiple Myeloma Hematology 2026 Standard Therapy Poland 56
386 Apheresis Autologous Anaplastic T Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Portugal 23
387 Apheresis Autologous Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 66
388 Apheresis Allogeneic T-Cell Lymphoma Hematology 2026 Standard Therapy Germany 55
389 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
390 Apheresis Autologous Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 53
391 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 56
392 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 69
393 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Lithuania 60
394 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 75
395 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Poland 58
396 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 74
397 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 69
398 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 70
399 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Canada 25
400 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Sweden 65